This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Hisamitsu Pharmaceutical Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los beneficios de Hisamitsu Pharmaceutical disminuyan en un 1.7% al año, mientras que se espera que sus ingresos anuales crezcan en un 4% al año. Se prevé que el BPA crezca en un 0.2% por año. Se espera que la rentabilidad financiera sea de 4.9% en 3 años.

Información clave

-1.7%

Tasa de crecimiento de los beneficios

0.21%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.5%
Tasa de crecimiento de los ingresos	4.0%
Rentabilidad financiera futura	4.90%
Cobertura de analistas	Low
Última actualización	25 Apr 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Artículo de análisis • Jan 06

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) shareholders have had their patience rewarded with a 25% share price...

Artículo de análisis • Jan 05

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Artículo de análisis • Dec 18

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its periodic dividend on the...

Artículo de análisis • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) periodic dividend will be increasing on the 7th of November to...

Artículo de análisis • Jun 27

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will increase its dividend on the 7th of November to ¥60.00, which is...

Artículo de análisis • Apr 18

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Unsurprisingly, Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) stock price was strong on the back of its healthy...

Artículo de análisis • Mar 07

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Artículo de análisis • Feb 17

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Artículo de análisis • Jan 13

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Artículo de análisis • Dec 30

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Artículo de análisis • Nov 27

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) will pay a dividend of ¥45.00 on the 26th of May. Based on this...

Artículo de análisis • Nov 08

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will pay a dividend of ¥45.00 per...

Artículo de análisis • Nov 04

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Artículo de análisis • Oct 17

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) healthy profit numbers didn't contain any surprises for investors. We...

Artículo de análisis • Sep 16

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...

Artículo de análisis • Aug 20

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc.'s ( TSE:4530 ) dividend will be increasing from last year's payment of the same...

Artículo de análisis • Jul 26

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

The board of Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be paying its dividend of...

Artículo de análisis • Jul 11

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Artículo de análisis • Jun 27

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Artículo de análisis • Jun 13

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) has announced that it will be increasing its dividend from last year's...

Artículo de análisis • Apr 09

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

With a price-to-earnings (or "P/E") ratio of 20.9x Hisamitsu Pharmaceutical Co., Inc. ( TSE:4530 ) may be sending...

Artículo de análisis • Mar 18

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Previsiones de crecimiento de beneficios e ingresos

TSE:4530 - Estimaciones futuras de los analistas y datos financieros pasados (JPY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
2/28/2029	176,797	13,067	N/A	16,324	1
2/29/2028	167,285	12,014	4,281	14,904	1
2/28/2027	159,685	11,973	5,665	16,289	1
2/28/2026	163,024	19,160	9,428	17,478	N/A
11/30/2025	159,267	19,988	N/A	N/A	N/A
8/31/2025	155,493	19,682	8,355	16,556	N/A
5/31/2025	154,861	19,534	N/A	N/A	N/A
2/28/2025	156,006	21,758	4,991	18,765	N/A
11/30/2024	150,132	15,537	N/A	N/A	N/A
8/31/2024	150,185	14,650	176	18,593	N/A
5/31/2024	145,420	14,708	N/A	N/A	N/A
2/29/2024	141,706	13,969	5,152	18,188	N/A
11/30/2023	139,276	14,330	N/A	N/A	N/A
8/31/2023	135,688	13,655	2,186	12,416	N/A
5/31/2023	134,033	14,160	N/A	N/A	N/A
2/28/2023	128,330	11,742	4,819	12,727	N/A
11/30/2022	125,411	12,962	N/A	N/A	N/A
8/31/2022	121,261	11,160	8,832	12,698	N/A
5/31/2022	118,825	8,927	N/A	N/A	N/A
2/28/2022	120,193	9,658	15,006	19,199	N/A
11/30/2021	120,351	9,746	N/A	N/A	N/A
8/31/2021	120,135	10,559	12,153	15,796	N/A
5/31/2021	117,389	11,499	N/A	N/A	N/A
2/28/2021	114,510	9,250	1,901	5,289	N/A
11/30/2020	122,736	8,996	N/A	N/A	N/A
8/31/2020	130,517	14,839	19,468	23,638	N/A
5/31/2020	136,641	16,894	N/A	N/A	N/A
2/29/2020	140,992	18,694	23,669	27,395	N/A
11/30/2019	139,912	21,295	N/A	N/A	N/A
8/31/2019	137,425	17,594	N/A	16,497	N/A
5/31/2019	139,142	17,665	N/A	N/A	N/A
2/28/2019	143,408	19,204	N/A	15,772	N/A
11/30/2018	140,891	16,608	N/A	N/A	N/A
8/31/2018	143,791	18,891	N/A	21,587	N/A
5/31/2018	145,288	18,897	N/A	N/A	N/A
2/28/2018	147,870	19,119	N/A	30,453	N/A
11/30/2017	145,749	17,895	N/A	N/A	N/A
8/31/2017	144,941	20,495	N/A	25,077	N/A
5/31/2017	143,853	19,540	N/A	N/A	N/A
2/28/2017	145,925	20,395	N/A	19,910	N/A
11/30/2016	149,298	20,806	N/A	N/A	N/A
8/31/2016	153,871	17,694	N/A	27,819	N/A
5/31/2016	160,325	18,778	N/A	N/A	N/A
2/29/2016	161,852	17,784	N/A	30,923	N/A
11/30/2015	164,086	19,626	N/A	N/A	N/A
8/31/2015	162,119	18,586	N/A	25,757	N/A
5/31/2015	158,667	18,321	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de 4530 disminuyan en los próximos 3 años (-1.7% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de 4530 disminuyan en los próximos 3 años (-1.7% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de 4530 disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (4% al año) de 4530 crezcan más despacio que el mercado de JP (6.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4% al año) de 4530 crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 4530 sea baja dentro de 3 años (4.9%).

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/05/14 15:19
Precio de las acciones al final del día	2026/05/08 00:00
Beneficios	2026/02/28
Ingresos anuales	2026/02/28

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Hisamitsu Pharmaceutical Co., Inc. está cubierta por 8 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Inc
Akitada Iwasa	Daiwa Securities Co. Ltd.

This company listing is no longer active

Hisamitsu Pharmaceutical Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Price target decreased by 10% to JP¥4,350

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Price target decreased by 15% to JP¥4,250

Recent updates

Hisamitsu Pharmaceutical Co., Inc.(TSE:4530) dropped from FTSE All-World Index (USD)

Full year 2026 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 28, 2026

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2026 Results on Apr 13, 2026

New major risk - Revenue and earnings growth

Taiyo Kosan Co., Ltd. completed the acquisition of additional 59.38% stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) from Takasago International Corporation (TSE:4914), Yomeishu Seizo Co.,Ltd. (TSE:2540), The Bank of Saga Ltd. (TSE:8395) and others for approximately ¥250 billion.

Third quarter 2026 earnings released: EPS: JP¥69.15 (vs JP¥62.32 in 3Q 2025)

Hisamitsu Pharmaceutical Co., Inc. Revises Dividend Guidance for the Fiscal Year Ending February 28, 2026

New minor risk - Share price stability

Taiyo Kosan Co., Ltd. agreed to acquire a %97.49 stake in Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) in a management buyout transaction for approximately ¥380.6 billion.

What Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) 25% Share Price Gain Is Not Telling You

Investor sentiment improves as stock rises 18%

These 4 Measures Indicate That Hisamitsu Pharmaceutical (TSE:4530) Is Using Debt Safely

Does Hisamitsu Pharmaceutical (TSE:4530) Deserve A Spot On Your Watchlist?

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥60.00

First half dividend of JP¥60.00 announced

Hisamitsu Pharmaceutical's (TSE:4530) Earnings Are Of Questionable Quality

Second quarter 2026 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of JP¥60.00 per share

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Price target decreased by 10% to JP¥4,350

First quarter 2026 earnings: EPS and revenues miss analyst expectations

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 3,000,000 shares, representing 4.09% for ¥15,000 million.

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥60.00

Final dividend increased to JP¥60.00

Consensus EPS estimates increase by 23%

Price target increased by 7.8% to JP¥4,850

We Think That There Are Issues Underlying Hisamitsu Pharmaceutical's (TSE:4530) Earnings

Hisamitsu Pharmaceutical Co., Inc. Announces Exiting of Sugiyama, Kosuke as Director

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 22, 2025

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2026 Results on Oct 09, 2025

With EPS Growth And More, Hisamitsu Pharmaceutical (TSE:4530) Makes An Interesting Case

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2025 Results on Apr 10, 2025

Upcoming dividend of JP¥45.00 per share

Does Hisamitsu Pharmaceutical (TSE:4530) Have A Healthy Balance Sheet?

Consensus EPS estimates increase by 12%

Price target increased by 8.0% to JP¥4,700

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be ¥45.00

Third quarter 2025 earnings released: EPS: JP¥62.32 (vs JP¥48.25 in 3Q 2024)

Hisamitsu Pharmaceutical Co., Inc. Announces Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical (TSE:4530) Is Due To Pay A Dividend Of ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

Hisamitsu Pharmaceutical Co., Inc. to Report Q3, 2025 Results on Jan 09, 2025

Hisamitsu Pharmaceutical (TSE:4530) Has Announced A Dividend Of ¥45.00

First half dividend of JP¥45.00 announced

We Think Hisamitsu Pharmaceutical (TSE:4530) Can Stay On Top Of Its Debt

Hisamitsu Pharmaceutical's (TSE:4530) Solid Earnings May Rest On Weak Foundations

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) Not Lagging Market On Growth Or Pricing

Upcoming dividend of JP¥45.00 per share

Hisamitsu Pharmaceutical's (TSE:4530) Shareholders Will Receive A Bigger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. to Report Q2, 2025 Results on Oct 10, 2024

Hisamitsu Pharmaceutical (TSE:4530) Has Announced That It Will Be Increasing Its Dividend To ¥45.00

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Hisamitsu Pharmaceutical (TSE:4530) Is Paying Out A Larger Dividend Than Last Year

Hisamitsu Pharmaceutical Co., Inc. Provides Commemorative Dividend for the Fiscal Year Ending February 28, 2025

Hisamitsu Pharmaceutical's (TSE:4530) Dividend Will Be Increased To ¥45.00

Hisamitsu Pharmaceutical (TSE:4530) Is Increasing Its Dividend To ¥45.00

Final dividend of JP¥45.00 announced

Hisamitsu Pharmaceutical Co., Inc. to Report Q1, 2025 Results on Jul 11, 2024

Hisamitsu Pharmaceutical Co., Inc. (TSE:4530) announces an Equity Buyback for 2,400,000 shares, representing 3.17% for ¥8,901.6 million.

Full year 2024 earnings: EPS misses analyst expectations

Hisamitsu Pharmaceutical Co., Inc., Annual General Meeting, May 23, 2024

Why We're Not Concerned About Hisamitsu Pharmaceutical Co., Inc.'s (TSE:4530) Share Price

Here's Why We Think Hisamitsu Pharmaceutical (TSE:4530) Is Well Worth Watching

Hisamitsu Pharmaceutical Co., Inc. to Report Fiscal Year 2024 Results on Apr 11, 2024